As acetylshikonin inhibited tumour growth in the mouse model only when the PDX tumour tissue expressed high levels of TOPK, and showed no marked side effects, the compound or its derivatives can be considered for further clinical development of molecular target‐based therapy for colorectal cancer. This evidence concerns the gene PBK and neoplasm.